Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
Introduction: Knowledge of longitudinal progression in mild Alzheimer’s disease (AD) is required for the evaluation of disease-modifying therapies. Our aim was to observe the effects of long-term cholinesterase inhibitor (ChEI) therapy in mild AD patients in a routine clinical setting. Methods: This was a prospective, open-label, non-randomised, multicentre study of ChEI treatment (donepezil, riva
